Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Vernalis plc and Lundbeck to Collaborate on Drug Discovery

By Pharmaceutical Processing | December 16, 2010

Vernalis plc and H. Lundbeck A/S have entered into a drug
discovery collaboration utilising Vernalis’ fragment and structure-based drug
discovery platform against LRRK2, a kinase target. Inhibitors of this target
may have potential utility in the treatment of neurodegenerative indications,
such as Parkinson’s Disease.

Under the terms of the collaboration Vernalis will receive
fees and a potential share in the downstream success of the product in the form
of milestones and royalties on sales.  The financial terms of this
collaboration are not disclosed.

Ian Garland, CEO of Vernalis, commented: “We are
delighted to be working with Lundbeck and look forward to a close working
relationship over the course of the collaboration.  The collaboration
announced today further endorses the quality of our fragment and
structure-based drug discovery platform and continues our success in securing
collaborations that allow us to maintain a balanced investment in research.”

“Lundbeck will get access to a state of the art
platform for fragment based drug discovery and structural biology. This
combined with their experience for discovering Kinase inhibitors and Lundbeck
CNS experience will ensure a strong alliance towards finding novel
medicines” said Klaus Bæk Simonsen, Head of Discovery Chemistry at H.
Lundbeck A/S.

 

Related Articles Read More >

Astellas
Astellas to spend $70M on new biotech campus in South San Francisco
Rainin
Mettler Toledo Rainin expands facilities in Vacaville, California
Elemental Machines
Elemental Machines aims to enlist lab freezers in fight against climate change 
Pfizer logo
Pfizer seeks to comply with voluntary Net-Zero Standard by 2040

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards